Eileen: Coping with Chemo

Eileen: Coping with Chemo

Cancer patients often hear the words: “You’re so brave! I could never go through that.” As if we have a choice or are selected based on our bravery. I know some are as the pretty-in-pink Wonder Woman who stares the cancer monster in the face, one stiletto heel on its chest with a fist waved in victory. That’s not me. Not to brag, but I’m a wimp. Any inner strength I possessed didn’t begin to prepare me for hearing the words, “You have breast cancer.” If I fought a valiant battle, it’s not because I was brave; it’s because I was scared.

Mary: Stage I Invasive Breast Cancer

Mary: Stage I Invasive Breast Cancer

My name is Mary Vetting, and I am an eight-year breast cancer survivor.

Most people think of breast cancer as an older woman’s disease. It turns out, however, that breast cancer is actually the most common cancer in women aged 15-39.

A cancer diagnosis is terrifying for anyone, but it was especially frightening for me as my Mother died of metastatic breast cancer in 1998, after a brave, 14-year battle, at age 55.

As much as I still miss her everyday, the silver lining is that she became my guardian angel in many ways, but specifically in that high-risk specialists began screening me for breast cancer through bi-yearly mammograms, sonograms, and MRIs at age 31 because my Mother was first diagnosed at age 41.

Therefore, my breast cancer was caught early, before it spread.

Terlisa: Survivor Grateful for Second, Third and Fourth Chance at Life!

Terlisa: Survivor Grateful for Second, Third and Fourth Chance at Life!

My name is Terlisa Sheppard, and in November 1998, at the age of 31, while I was 34 weeks pregnant with my second child, I was diagnosed with Stage III breast cancer.

I had been complaining to my gynecologist about feeling a lump under my arm but he informed me that it was probably a milk duct that had formed due to the pregnancy and told me not to worry about it.

Announcing SHARE’s National Expansion

New Support Groups Active in Norwalk, CT; Brentwood, NY; and Orlando, FL
After 42 years in New York City, SHARE Cancer Support has announced a national expansion effort. Norwalk, CT; Brentwood, Long Island, NY; and Orlando, FL are the first cities outside New York City to offer SHARE’s in-person services to women with breast or ovarian cancers.

Introducing new program formats!

If you receive our program calendar or email newsletter, you may have noticed some new types of educational programs. In addition to our webinars and in-person programs, we are now offering interactive educational opportunities through other platforms. These new kinds of programs offer the same quality content, and make it easy for you to engage with the presenters.

SHARE Expands Chinese Outreach

SHARE has long been a leader in outreach to medically underserved communities. This year, SHARE connected with the Charles B. Wang Community Health Center to seek ways to better support the Chinese community in New York City with its free breast and ovarian cancer services.

Learn how to make authentic Mexican dishes from award-winning chef Barbara Sibley

We recently joined Chef Barbara Sibley at La Palapa Cocina Mexicana Restaurant for a demonstration of tasty nutritional foods from Mexico. Check out these delicious wholesome foods below, and watch the demonstration on Facebook Live.

Guacamole de La Palapa
Makes about 2 cups; serves 4 to 6

2 large avocados, preferably Mexican, halved and pitted
½ sweet onion, such as Vidalia finely chopped
½ cup chopped fresh cilantro leaves
1 to 2 serrano or jalapeño chiles, finely chopped ~ to taste!
About 1½ tablespoons freshly squeezed lime juice
Kosher salt

Using a tablespoon, scoop out the avocado pulp into a small bowl.

Treating Endocrine-Resistant Metastatic Breast Cancer

In September, the FDA approved amebaciclib (Verzenio), the latest drug to treat endocrine resistant metastatic breast cancer (MBC). In combination with fulvestrant (Faslodex), the results of the phase III, Monarch 2 trial showed an improvement in progression free survival (PFS). All the patients in the trial were hormone receptor positive and HER2 negative, as are all the enrollees in the trials noted here.

Update on TAPUR Study

At its annual meeting this year in June, the American Society of Clinical Oncology (ASCO) gave patient advocates an update on the TAPUR clinical trial, which is its first trial. The trial was rolled out about two years ago.

The TAPUR trial (Targeted Agent and Profiling Utilization Registry) allows us to obtain FDA-approved drugs free-of-charge by cutting out the red tape when we are no longer benefiting from any standard treatment.

National Helpline: